



Listing and evaluation of the results

51396: Dr. Endre Mikus
LabMagister Training and Science Ltd.

Survey of 12 September 2018

Adviser:

Prof. Dr. med. Kai Gutensohn

MVZ aescuLabor Hamburg GmbH - amedes
Haferweg 36
22769 Hamburg

Tel.: +49 40 334411 880

Mail: kai.gutensohn@amedes-group.com

217

Haematology 11 - Stem/Progenitor Cells (CD 34)

Analyte	Sam- ple	Unit	Your value	Target value	TV- Type	Lower limit	Upper limit	Deviation	Meets criteria	
CD34+ Events	51	/µl	79.0	92.6	SV	74.1	111	-14.7%	+	
	52	/µl	61.0	65.3	SV	52.2	78.4	-6.6%	+	
CD45+ events (single platform)	51	/µl	17051	16878	SV	13502	20254			
	52	/µl	14700	14373	SV	11498	17248			
Viable CD45+ Events	51	/µl	12444	12041	SV	9633	14449			
	52	/µl	10340	10023	SV	8018	12028			
Viable CD34+ Events	51	/µl	73.0	90.3	SV	72.2	108	-19.2%	+	
	52	/µl	56.0	63.4	SV	50.7	76.1	-11.7%	+	
Viable CD34+ Events per viable CD45+ Events	51	%	0.590	0.753	SV	0.602	0.904			
	52	%	0.540	0.636	SV	0.509	0.763			



Analyte	Sam- ple	Your unit	Stated value	Conversion factor	Method	Manu- facturer	Device	Sample reception date	Sample processing date
CD34+ Events	51		79.0	1.00	222	ZY	BN04	09/05/18	09/05/18
	52		61.0	1.00					
CD45+ events (single platform)	51		17051		222	ZY	BN04	09/05/18	09/05/18
	52		14700						
Viable CD45+ Events	51		12444		222	ZY	BN04	09/05/18	09/05/18
	52		10340						
Viable CD34+ Events	51		73.0	1.00	222	ZY	BN04	09/05/18	09/05/18
	52		56.0	1.00					
Viable CD34+ Events per viable CD45+ Events	51		0.590		222	ZY	BN04	09/05/18	09/05/18
	52		0.540						



CD34+ Events (/μl, N = 96)

Collective	Sample	Target value	Review area	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	51	92.6	74.1 - 111	92.6	10.4	96	90.6	84.4
	52	65.3	52.2 - 78.4	65.3	9.25	96	92.7	


Rate of success: 84,4%



CD45+ events (single platform) (/μl, N = 85)

Collective	Sample	Target value	Review area	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	51	16878	13502 - 20254	16878	6.94	85		
	52	14373	11498 - 17248	14373	7.74	85		


Rate of success: 97,6%



Viable CD45+ Events (/μl, N = 108)

Collective	Sample	Target value	Review area	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	51	12041	9633 - 14449	12041	10.4	108		
	52	10023	8018 - 12028	10023	12.3	108		



Rate of success: 80,6%



Viable CD34+ Events (/μl, N = 108)

Collective	Sam- ple	Target value	Review area	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	51	90.3	72.2 - 108	90.3	9.73	108	90.7	88.0
	52	63.4	50.7 - 76.1	63.4	9.78	108	90.7	

Rate of success: 88%



Viable CD34+ Events per viable CD45+ Events (% , N = 108)

Collective	Sam- ple	Target value	Review area	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	51	0.753	0.602 - 0.904	0.753	11.3	108		
	52	0.636	0.509 - 0.763	0.636	11.5	108		

Rate of success: 80,6%

